CA
NZ
UK
AU
IND
US
Korro Bio, Inc. (NASDAQ: KRRO) has executed an exchange agreement with Venrock Healthcare Capital Partners to issue 1 million pre-funded warrants. This strategic move involves Venrock surrendering 1 million shares of Korro's common stock to the company at no cost, enhancing Korro's financial agility. …
The company's earnings per share (EPS) reached $0.02, surpassing the $-0.02 consensus estimate. This marks a significant performance uplift amid Evolent's efforts to deliver complex healthcare solutions, essential for investor confidence. The year-to-date revenue performance is a positive indicator of what lies ahead for …
Foghorn Therapeutics Inc. (NASDAQ: FHTX) posted a net loss of $7.2 million for the second quarter ended June 30, reflecting a significant improvement from the prior year's loss of $17.9 million. The company reported an earnings per share (EPS) of $-0.29, surpassing analyst expectations, …
The broader context shows that the company faced a challenging performance, particularly as it missed the consensus estimate for earnings per share (EPS), reporting a loss of $-1.06 against expectations of $-0.51. This drop in revenue highlights potential operational challenges that could deter investor …
Geron Corp's (NASDAQ: GERN) financial results reveal an earnings per share (EPS) of $-0.02 for the quarter ended June 30, 2026, slightly lagging behind the consensus estimate of $-0.01. This marks a challenging period for the biopharmaceutical company, particularly as it grapples with soaring …
Haemonetics Corp (NYSE: HAE) reported $339 million in revenue for the first quarter of fiscal 2027, demonstrating a 5.6% rise from the previous year. This solid performance is key as it signifies the company’s successful execution of its growth strategies, particularly in the plasma …
Harrow, Inc. (NASDAQ: HROW) will acquire global rights to the TYRVAYA nasal spray for $30 million, with additional milestone payments totaling up to $70 million based on annual sales thresholds. This transaction represents a significant strategic move for the company, enhancing its existing dry …
Eli Lilly’s rapid ascent in the obesity treatment market is underscored by nearly $27.7 billion in sales from its injectable GLP-1 drugs, significantly widening its gap with Novo Nordisk, which now lags behind by more than $10 billion. This expansion reflects a strong market …
Enovis CORP (NYSE: ENOV) unveiled its financial results for the second quarter ending on July 3, 2026, reporting net sales of $583 million, a 3% increase from the same quarter last year. The company's strong performance was bolstered by an 8% rise in its …
This strategic move is expected to bolster Ensysce's operational capabilities and growth in the competitive biotechnology environment.
Please wait processing your request...